Trial Profile
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study Of Efficacy And Safety Of Enzalutamide In Combination With Exemestane In Patients With Advanced Breast Cancer That Is Estrogen Or Progesterone Receptor-positive And Her2-normal
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 25 Apr 2023 Planned End Date changed from 31 Mar 2023 to 31 Dec 2023.
- 18 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Mar 2023.
- 20 Dec 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.